for each share of class a common stock issued by evolent health , inc. , the company received a corresponding class a common unit from evolent health llc in exchange for contributing the issuance proceeds to evolent health llc . as a result of the class a common stock and class a common units of evolent health llc issued during the august 2017 primary , the company 's economic interest in evolent health llc increased from 96.1 % to 96.6 % immediately following the august 2017 primary , and , accordingly , the company reclassified a portion of its non-controlling interests into shareholders ' equity attributable to evolent health , inc. 41 2017 secondary offerings certain affiliates of tpg , the advisory board , upmc and ptolemy capital ( together , the “ investor stockholders ” ) have an existing exchange right that allows receipt of newly-issued shares of the company 's class a common stock in exchange ( a “ class b exchange ” ) for an equal number of shares of the company 's class b common stock ( which are subsequently canceled ) and an equal number of evolent health llc 's class b common units . the class b common units of evolent health llc received by the company from relevant investor stockholders are simultaneously exchanged for an equivalent number of class a common units of evolent health llc , and evolent health llc cancels the class b common units of evolent health llc it receives in the class b exchange . the class b exchanges and subsequent cancellation of class b common units of evolent health llc result in an increase in the company 's economic interest in evolent health llc . the company did not receive any proceeds from class b exchanges or the sale of class a common stock in the secondary offerings described below . the investor stockholders initiated several class b exchanges as part of various secondary offerings during 2017 , thus increasing the company 's economic interest in evolent health llc , as discussed below . june 2017 secondary offering in june 2017 , the company completed a secondary offering of 4.5 million shares of its class a common stock at a price to the underwriters of $ 25.87 per share ( the “ june 2017 secondary ” ) . the shares sold in the june 2017 secondary consisted of 0.7 million existing shares of the company 's class a common stock owned and held by certain investor stockholders and 3.8 million newly issued shares of the company 's class a common stock received by certain investor stockholders pursuant to class b exchanges . as a result of these class b exchanges and evolent health llc 's cancellation of its class b common units during the june 2017 secondary , the company 's economic interest in evolent health llc increased from 90.5 % to 96.1 % immediately following the june 2017 secondary , and , accordingly , the company reclassified a portion of its non-controlling interests into shareholders ' equity attributable to evolent health , inc. may 2017 secondary offering in may 2017 , the company completed a secondary offering of 7.0 million shares of its class a common stock at a price to the underwriters of $ 24.30 per share ( the “ may 2017 secondary ” ) . the shares were sold by the investor stockholders and certain management selling stockholders ( together with the investor stockholders , the “ selling stockholders ” ) . the shares sold in the may 2017 secondary consisted of 3.1 million existing shares of the company 's class a common stock owned and held by the selling stockholders , 3.8 million newly issued shares of the company 's class a common stock received by certain investor stockholders pursuant to class b exchanges and 0.1 million shares issued upon the exercise of options by certain management selling stockholders . as a result of these class b exchanges and evolent health llc 's cancellation of its class b common units during the may 2017 secondary , the company 's economic interest in evolent health llc increased from 84.9 % to 90.5 % immediately following the may 2017 secondary , and , accordingly , the company reclassified a portion of its non-controlling interests into shareholders ' equity attributable to evolent health , inc. march 2017 secondary offering in march 2017 , the company completed a secondary offering of 7.5 million shares of its class a common stock at a price to the underwriters of $ 19.53 per share ( the “ march 2017 secondary ” ) . the shares sold in the march 2017 secondary consisted of 3.1 million existing shares of the company 's class a common stock owned and held by the investor stockholders and 4.4 million newly issued shares of the company 's class a common stock received by certain investor stockholders pursuant to class b exchanges . as a result of these class b exchanges and evolent health llc 's cancellation of its class b common units during the march 2017 secondary , the company 's economic interest in evolent health llc increased from 77.4 % to 83.9 % immediately following the march 2017 secondary , and , accordingly , the company reclassified a portion of its non-controlling interests into shareholders ' equity attributable to evolent health , inc. in connection with the march 2017 secondary , the underwriters exercised , in full , their option to purchase an additional 1.1 million shares of class a common stock ( the “ march 2017 option to purchase additional shares ” ) from the investor stockholders at a price of $ 19.53 per share . the march 2017 option to purchase additional shares closed on may 1 , 2017 . story_separator_special_tag subsequent to our 2015 annual impairment testing , our common stock price declined significantly , reaching our historic low in the first quarter of 2016. during the three months ended march 31 , 2016 , our common stock traded between $ 8.48 and $ 12.32 , or an average common stock price of $ 10.33 compared to an average common stock price of $ 19.51 and $ 14.73 during the three month periods ended september 30 , 2015 , and december 31 , 2015 , respectively . a sustained decline in our common stock price and the resulting impact on our market capitalization is one of several qualitative factors we consider each quarter when evaluating whether events or changes in circumstances indicate it is more likely than not that a potential goodwill impairment exists . we concluded that the further decline in common stock price observed during the first quarter of 2016 did represent a sustained decline and that triggering events occurred during the period requiring an interim goodwill impairment test as of march 31 , 2016. as such , we performed a step 1 impairment test of our goodwill as of march 31 , 2016. step 1 results to determine the implied fair value for our single reporting unit , we used both a market approach and income approach , as described above . in our march 31 , 2016 , step 1 test , our most sensitive assumption for purposes of the market approach was our estimate of the control premium , and the most sensitive assumption related to the income approach , other than the projected cash flows , was the discount rate . as of march 31 , 2016 , our single reporting unit failed the step 1 analysis as we determined that its implied fair value was less than its carrying value based on the weighting of the fair values determined under both the market and income approaches . as fair value was less than carrying value , we performed a step 2 test to determine the implied fair value of our goodwill . step 2 results in our march 31 , 2016 , step 2 test , the fair value of all assets and liabilities was estimated , including our tangible assets ( corporate trade name , customer relationships and technology ) , for the purpose of deriving an estimate of the implied fair value of goodwill . the implied fair value of goodwill was then compared to the carrying amount of goodwill , resulting in an impairment charge of $ 160.6 million on our consolidated statements of operations . the impairment was driven primarily by the sustained decline in our share price as our estimates of our future cash flows and the control premium have remained consistent , combined with an increase in the discount rate period over period . as noted above , our determination of fair value used a weighting of the fair values determined under both the market and income approaches , with the market approach driving the significant reduction in overall firm value and related impairment of goodwill . 46 on october 31 , 2016 , the company performed its annual goodwill impairment review for fiscal year 2016 . based on our qualitative assessment , we did not identify sufficient indicators of impairment that would suggest fair value was below carrying value . as a result , a quantitative step 1 goodwill impairment analysis was not required . as of december 31 , 2016 , evolent assessed whether there were events or changes in circumstances that would more likely than not reduce the fair value of its goodwill below its carrying amount and require an additional impairment test . the company determined that there have been no such indicators . therefore , it was unnecessary to perform an interim goodwill impairment assessment as of december 31 , 2016 . intangible assets , net intangible assets are reviewed for impairment if circumstances indicate the company may not be able to recover the asset 's carrying value . examples of such circumstances include a significant decrease in the market price of a long-lived asset , a significant adverse change in the extent or manner in which a long-lived asset is being used or in its physical condition , or a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset . the company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date . if the undiscounted cash flows are not sufficient to cover the carrying value , the company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value . the estimation of future undiscounted cash flows expected to result from the use and disposition of an asset or group requires significant judgment and future results may vary from current assumptions . as discussed above , we identified a triggering event and performed a quantitative analysis over the carrying value of our goodwill balance during the fourth quarter of 2017. identification of the triggering event also triggered an impairment analysis of the carrying value of our intangible asset group . in conjunction with the impairment testing of the carrying value of our goodwill , we performed an analysis to determine whether the carrying amount of our intangible asset group was recoverable . we performed a quantitative analysis , which required management to compare the total pre-tax , undiscounted future cash flows of the intangible asset group to the current carrying amount . the total undiscounted cash flows included only the future cash flows that are directly associated with and that were expected to arise as a result of the use and eventual disposal of the asset group . based on our quantitative analysis , we determined that the

cash flows used in investing activities of $ 12.3 million in 2017 , primarily relate to purchases of property and equipment of $ 27.8 million , payment of a $ 20.0 million implementation funding loan , purchases of restricted investments of $ 3.8 million and cash paid to acquire intangible technology assets of $ 3.7 million . these amounts were partially offset by the maturity of investment securities in the amount of $ 44.2 million . cash flows used in investing activities of $ 96.7 million in 2016 were due primarily to cash outflows for the acquisitions of valence health and aldera for $ 53.7 million and $ 17.5 million , respectively . we also paid $ 11.5 million in connection with our acquisition of vestica 's assets and $ 3.0 million for our equity investment in gpac . purchases of property and equipment and restricted investments resulted in further cash outflows of $ 15.5 million and $ 5.0 million , respectively , during the year . these amounts were partially offset by the maturity of investment securities in the amount of $ 9.4 million . cash flows used in investing activities of $ 43.7 million in 2015 were due primarily to the investment of a portion of our ipo proceeds into held-to-maturity investments of $ 54.2 million and the purchase of $ 6.5 million of property and equipment , partially offset by cash acquired upon the consolidation of evolent health llc of $ 13.1 million and maturities of investments of $ 4.0 million . financing activities cash flows provided by financing activities of $ 165.6 million in 2017 were primarily related to proceeds of $ 166.9 million from the august 2017 primary . stock option exercises during the quarter resulted in additional proceeds of $ 4.1 million , which were partially offset by $ 1.3 million of taxes withheld and paid for vests of restricted stock units . the inflows were further offset by a $ 4.2 million reduction in the amount of restricted cash held on behalf of our partners to process pbm and other claims .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows used in investing activities of $ 12.3 million in 2017 , primarily relate to purchases of property and equipment of $ 27.8 million , payment of a $ 20.0 million implementation funding loan , purchases of restricted investments of $ 3.8 million and cash paid to acquire intangible technology assets of $ 3.7 million . these amounts were partially offset by the maturity of investment securities in the amount of $ 44.2 million . cash flows used in investing activities of $ 96.7 million in 2016 were due primarily to cash outflows for the acquisitions of valence health and aldera for $ 53.7 million and $ 17.5 million , respectively . we also paid $ 11.5 million in connection with our acquisition of vestica 's assets and $ 3.0 million for our equity investment in gpac . purchases of property and equipment and restricted investments resulted in further cash outflows of $ 15.5 million and $ 5.0 million , respectively , during the year . these amounts were partially offset by the maturity of investment securities in the amount of $ 9.4 million . cash flows used in investing activities of $ 43.7 million in 2015 were due primarily to the investment of a portion of our ipo proceeds into held-to-maturity investments of $ 54.2 million and the purchase of $ 6.5 million of property and equipment , partially offset by cash acquired upon the consolidation of evolent health llc of $ 13.1 million and maturities of investments of $ 4.0 million . financing activities cash flows provided by financing activities of $ 165.6 million in 2017 were primarily related to proceeds of $ 166.9 million from the august 2017 primary . stock option exercises during the quarter resulted in additional proceeds of $ 4.1 million , which were partially offset by $ 1.3 million of taxes withheld and paid for vests of restricted stock units . the inflows were further offset by a $ 4.2 million reduction in the amount of restricted cash held on behalf of our partners to process pbm and other claims .
```    
 Suspicious Activity Report : for each share of class a common stock issued by evolent health , inc. , the company received a corresponding class a common unit from evolent health llc in exchange for contributing the issuance proceeds to evolent health llc . as a result of the class a common stock and class a common units of evolent health llc issued during the august 2017 primary , the company 's economic interest in evolent health llc increased from 96.1 % to 96.6 % immediately following the august 2017 primary , and , accordingly , the company reclassified a portion of its non-controlling interests into shareholders ' equity attributable to evolent health , inc. 41 2017 secondary offerings certain affiliates of tpg , the advisory board , upmc and ptolemy capital ( together , the “ investor stockholders ” ) have an existing exchange right that allows receipt of newly-issued shares of the company 's class a common stock in exchange ( a “ class b exchange ” ) for an equal number of shares of the company 's class b common stock ( which are subsequently canceled ) and an equal number of evolent health llc 's class b common units . the class b common units of evolent health llc received by the company from relevant investor stockholders are simultaneously exchanged for an equivalent number of class a common units of evolent health llc , and evolent health llc cancels the class b common units of evolent health llc it receives in the class b exchange . the class b exchanges and subsequent cancellation of class b common units of evolent health llc result in an increase in the company 's economic interest in evolent health llc . the company did not receive any proceeds from class b exchanges or the sale of class a common stock in the secondary offerings described below . the investor stockholders initiated several class b exchanges as part of various secondary offerings during 2017 , thus increasing the company 's economic interest in evolent health llc , as discussed below . june 2017 secondary offering in june 2017 , the company completed a secondary offering of 4.5 million shares of its class a common stock at a price to the underwriters of $ 25.87 per share ( the “ june 2017 secondary ” ) . the shares sold in the june 2017 secondary consisted of 0.7 million existing shares of the company 's class a common stock owned and held by certain investor stockholders and 3.8 million newly issued shares of the company 's class a common stock received by certain investor stockholders pursuant to class b exchanges . as a result of these class b exchanges and evolent health llc 's cancellation of its class b common units during the june 2017 secondary , the company 's economic interest in evolent health llc increased from 90.5 % to 96.1 % immediately following the june 2017 secondary , and , accordingly , the company reclassified a portion of its non-controlling interests into shareholders ' equity attributable to evolent health , inc. may 2017 secondary offering in may 2017 , the company completed a secondary offering of 7.0 million shares of its class a common stock at a price to the underwriters of $ 24.30 per share ( the “ may 2017 secondary ” ) . the shares were sold by the investor stockholders and certain management selling stockholders ( together with the investor stockholders , the “ selling stockholders ” ) . the shares sold in the may 2017 secondary consisted of 3.1 million existing shares of the company 's class a common stock owned and held by the selling stockholders , 3.8 million newly issued shares of the company 's class a common stock received by certain investor stockholders pursuant to class b exchanges and 0.1 million shares issued upon the exercise of options by certain management selling stockholders . as a result of these class b exchanges and evolent health llc 's cancellation of its class b common units during the may 2017 secondary , the company 's economic interest in evolent health llc increased from 84.9 % to 90.5 % immediately following the may 2017 secondary , and , accordingly , the company reclassified a portion of its non-controlling interests into shareholders ' equity attributable to evolent health , inc. march 2017 secondary offering in march 2017 , the company completed a secondary offering of 7.5 million shares of its class a common stock at a price to the underwriters of $ 19.53 per share ( the “ march 2017 secondary ” ) . the shares sold in the march 2017 secondary consisted of 3.1 million existing shares of the company 's class a common stock owned and held by the investor stockholders and 4.4 million newly issued shares of the company 's class a common stock received by certain investor stockholders pursuant to class b exchanges . as a result of these class b exchanges and evolent health llc 's cancellation of its class b common units during the march 2017 secondary , the company 's economic interest in evolent health llc increased from 77.4 % to 83.9 % immediately following the march 2017 secondary , and , accordingly , the company reclassified a portion of its non-controlling interests into shareholders ' equity attributable to evolent health , inc. in connection with the march 2017 secondary , the underwriters exercised , in full , their option to purchase an additional 1.1 million shares of class a common stock ( the “ march 2017 option to purchase additional shares ” ) from the investor stockholders at a price of $ 19.53 per share . the march 2017 option to purchase additional shares closed on may 1 , 2017 . story_separator_special_tag subsequent to our 2015 annual impairment testing , our common stock price declined significantly , reaching our historic low in the first quarter of 2016. during the three months ended march 31 , 2016 , our common stock traded between $ 8.48 and $ 12.32 , or an average common stock price of $ 10.33 compared to an average common stock price of $ 19.51 and $ 14.73 during the three month periods ended september 30 , 2015 , and december 31 , 2015 , respectively . a sustained decline in our common stock price and the resulting impact on our market capitalization is one of several qualitative factors we consider each quarter when evaluating whether events or changes in circumstances indicate it is more likely than not that a potential goodwill impairment exists . we concluded that the further decline in common stock price observed during the first quarter of 2016 did represent a sustained decline and that triggering events occurred during the period requiring an interim goodwill impairment test as of march 31 , 2016. as such , we performed a step 1 impairment test of our goodwill as of march 31 , 2016. step 1 results to determine the implied fair value for our single reporting unit , we used both a market approach and income approach , as described above . in our march 31 , 2016 , step 1 test , our most sensitive assumption for purposes of the market approach was our estimate of the control premium , and the most sensitive assumption related to the income approach , other than the projected cash flows , was the discount rate . as of march 31 , 2016 , our single reporting unit failed the step 1 analysis as we determined that its implied fair value was less than its carrying value based on the weighting of the fair values determined under both the market and income approaches . as fair value was less than carrying value , we performed a step 2 test to determine the implied fair value of our goodwill . step 2 results in our march 31 , 2016 , step 2 test , the fair value of all assets and liabilities was estimated , including our tangible assets ( corporate trade name , customer relationships and technology ) , for the purpose of deriving an estimate of the implied fair value of goodwill . the implied fair value of goodwill was then compared to the carrying amount of goodwill , resulting in an impairment charge of $ 160.6 million on our consolidated statements of operations . the impairment was driven primarily by the sustained decline in our share price as our estimates of our future cash flows and the control premium have remained consistent , combined with an increase in the discount rate period over period . as noted above , our determination of fair value used a weighting of the fair values determined under both the market and income approaches , with the market approach driving the significant reduction in overall firm value and related impairment of goodwill . 46 on october 31 , 2016 , the company performed its annual goodwill impairment review for fiscal year 2016 . based on our qualitative assessment , we did not identify sufficient indicators of impairment that would suggest fair value was below carrying value . as a result , a quantitative step 1 goodwill impairment analysis was not required . as of december 31 , 2016 , evolent assessed whether there were events or changes in circumstances that would more likely than not reduce the fair value of its goodwill below its carrying amount and require an additional impairment test . the company determined that there have been no such indicators . therefore , it was unnecessary to perform an interim goodwill impairment assessment as of december 31 , 2016 . intangible assets , net intangible assets are reviewed for impairment if circumstances indicate the company may not be able to recover the asset 's carrying value . examples of such circumstances include a significant decrease in the market price of a long-lived asset , a significant adverse change in the extent or manner in which a long-lived asset is being used or in its physical condition , or a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset . the company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date . if the undiscounted cash flows are not sufficient to cover the carrying value , the company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value . the estimation of future undiscounted cash flows expected to result from the use and disposition of an asset or group requires significant judgment and future results may vary from current assumptions . as discussed above , we identified a triggering event and performed a quantitative analysis over the carrying value of our goodwill balance during the fourth quarter of 2017. identification of the triggering event also triggered an impairment analysis of the carrying value of our intangible asset group . in conjunction with the impairment testing of the carrying value of our goodwill , we performed an analysis to determine whether the carrying amount of our intangible asset group was recoverable . we performed a quantitative analysis , which required management to compare the total pre-tax , undiscounted future cash flows of the intangible asset group to the current carrying amount . the total undiscounted cash flows included only the future cash flows that are directly associated with and that were expected to arise as a result of the use and eventual disposal of the asset group . based on our quantitative analysis , we determined that the

